Evansville Cancer Center Awarded Grant from AstraZeneca and
Teaming with Tri-State Urologists to Offer Free Prostate Screenings.
May 19, 2003 - Evansville Cancer Center has been awarded a grant from AstraZeneca Pharmaceutical to offer free prostate cancer screenings to industry work-sites. The screenings will consist of a digital rectal exam (DRE) and a prostate specific antigen (PSA) by board certified physicians.
Prostate cancer is the most common type of cancer found in American men, other than skin cancer. It is estimated that there will be 220,900 new cases of prostate cancer in the United States this year alone. Approximately 28,900 men will lose their lives to it.
It is recommended by the American Cancer Society that men age 50 and over and those 40-49 with a family history of prostate cancer or who are African-American, be screened for this disease. Early detection of this disease is critical because prompt diagnosis can lead to cure. The disease can develop without symptoms. Therefore, it is important that those at risk are screened periodically.
Evansville Cancer Center working in cooperation with Urological Associates, Urology Consultants, Dr. Paul Siami of Welborn Clinic, AstraZeneca, and LabCorp will be conducting educational offerings and screenings for prostate cancer at area industries. Participating industries are: Alcoa, American General Finance, Atlas Van Lines, Berry Plastics, D-Patrick, Escalade Sports, Evansville Courier Company, Ferro Corporation, PPG Industries, Vectren and Whirlpool. The first industrial work-site participating in the prostate cancer screening will be at Alcoa Warrick Operations on Thursday, May 22nd from 11:30 a.m. to 7:00 p.m. and Friday, May 23rd from 6:00 a.m. to 12:30 p.m.
Our goals are to raise prostate cancer awareness, to teach men the importance of taking charge of their health, and the promotion of early detection of prostate cancer.
Contact: Robin Lawrence-Broesch, Director of Marketing, at (812) 474-1110.